184 related articles for article (PubMed ID: 22234627)
81. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
82. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
Vocaturo A; Novelli F; Benevolo M; Piperno G; Marandino F; Cianciulli AM; Merola R; Donnorso RP; Sperduti I; Buglioni S; Mottolese M
Oncologist; 2006 Sep; 11(8):878-86. PubMed ID: 16951391
[TBL] [Abstract][Full Text] [Related]
83. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
[TBL] [Abstract][Full Text] [Related]
84. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
85. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
86. Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer.
Rossi V; Sarotto I; Maggiorotto F; Berchialla P; Kubatzki F; Tomasi N; Redana S; Martinello R; Valabrega G; Aglietta M; Ponzone R; Montemurro F
Oncologist; 2012; 17(11):1418-25. PubMed ID: 22951668
[TBL] [Abstract][Full Text] [Related]
87. Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer.
Yu KD; Liu GY; Zhou XY; Zhou Y; Wu J; Chen CM; Shen ZZ; Shao ZM
Oncologist; 2012; 17(6):792-800. PubMed ID: 22561335
[TBL] [Abstract][Full Text] [Related]
88. Trastuzumab for small HER-2+ breast cancer: small tumor, big decision.
Connolly RM; Bardia A
Oncologist; 2012; 17(4):508-11. PubMed ID: 22491004
[TBL] [Abstract][Full Text] [Related]
89. Trastuzumab and chemotherapy may be appropriate for small, node-negative, HER2-positive breast cancer.
Morris PG; McArthur HL
Oncologist; 2012; 17(10):e33; author reply e34. PubMed ID: 23104173
[TBL] [Abstract][Full Text] [Related]
90. A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer.
Bussolati G; Montemurro F; Righi L; Donadio M; Aglietta M; Sapino A
Br J Cancer; 2005 Apr; 92(7):1261-7. PubMed ID: 15812476
[TBL] [Abstract][Full Text] [Related]
91. Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment-a retrospective cohort study.
Wang J; Qiao J; Ruan Y; Wang C; Li L; Lu Z; Sun X; Zhang C; Chen X; Yan M; Cui S; Liu Z
Gland Surg; 2022 Dec; 11(12):1887-1896. PubMed ID: 36654959
[TBL] [Abstract][Full Text] [Related]
92. Relationship between
Adamczyk A; Kruczak A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Janecka-Widła A; Majchrzyk K; Cichocka A; Ryś J; Niemiec J
Onco Targets Ther; 2018; 11():4525-4535. PubMed ID: 30122944
[TBL] [Abstract][Full Text] [Related]
93. Breast cancer patients should not live without a HER-2/neu tissue result--but how safe can they live with it?
Lüftner D
Wien Klin Wochenschr; 2004 Jan; 116(1-2):3-5. PubMed ID: 15030116
[No Abstract] [Full Text] [Related]
94. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
Jung EJ; Santarpia L; Kim J; Esteva FJ; Moretti E; Buzdar AU; Di Leo A; Le XF; Bast RC; Park ST; Pusztai L; Calin GA
Cancer; 2012 May; 118(10):2603-14. PubMed ID: 22370716
[TBL] [Abstract][Full Text] [Related]
95. Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes.
Ahn HK; Park YH; Lee SJ; Park S; Maeng CH; Park W; Choi DH; Hur SJ; Ahn JS; Im YH
Springerplus; 2013 Dec; 2(1):136. PubMed ID: 23667803
[TBL] [Abstract][Full Text] [Related]
96. Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab.
Li F; Ju Q; Gao C; Li J; Wang X; Yan M; Zhang L; Huang M; Long Q; Jin X; Li N
Front Oncol; 2022; 12():819818. PubMed ID: 35311143
[TBL] [Abstract][Full Text] [Related]
97. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.
Hayashi N; Iwamoto T; Gonzalez-Angulo AM; Ferrer-Lozano J; Lluch A; Niikura N; Bartholomeusz C; Nakamura S; Hortobagyi GN; Ueno NT
Oncologist; 2011; 16(7):956-65. PubMed ID: 21712485
[TBL] [Abstract][Full Text] [Related]
98. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy.
Rexer BN; Shyr Y; Arteaga CL
J Clin Oncol; 2013 Jun; 31(17):2073-5. PubMed ID: 23650407
[No Abstract] [Full Text] [Related]
99. Efficacy of Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Acute Intracranial Hypertension Because of Brain Metastases.
Dufour O; Bertucci F; Boudin L; Sabatier R; Gonçalves A; de Nonneville A
JCO Precis Oncol; 2023 May; 7():e2200520. PubMed ID: 37224428
[No Abstract] [Full Text] [Related]
100. Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer.
Wang F; Azim QU; Sohail A; Nutini A; Arif R; R S Tavares JM
Saudi J Biol Sci; 2022 Jan; 29(1):123-131. PubMed ID: 35002400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
